A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Inclusion Criteria:

• Patients who are participating in the patisiran parent studies ALN-TTR02-011 orALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parentstudy ALN-TTRSC02-003

Exclusion Criteria:

• Has permanently discontinued study drug administration while participating in theparent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003

• Future or current participation in another investigational device or drug study,scheduled to occur during this study

• Has other medical conditions or comorbidities which, in the opinion of theInvestigator, would interfere with study compliance or data interpretation